Human IL-2 as a vaccine adjuvant

Details Human IL-2 as a vaccine adjuvant Human IL-2 as a vaccine adjuvant

1998-08-31

2000-05-09

Mertz, Prema

Drug, bio-affecting and body treating compositions

Nonspecific immunoeffector, per se ; or nonspecific...

424 852, 4242071, 4242091, 4242241, 4242411, 4242551, 4242561, 4242611, 514885, 530351, 530402, A61K 3820, A61K 3902, A61K 3912

Patent

active

060600683

ABSTRACT:
Methods for enhancing the immune response to vaccination in animals, including humans, comprise administering interleukin-2 (IL-2) as part of the vaccination regimen, preferably for 5 to 14 days post-vaccination. In addition, compositions for enhancing the immune response of an animal to a vaccine employ IL-2 as an active ingredient, preferably human IL-2.

REFERENCES:
patent: 3674862 (1972-07-01), Lavender
patent: 4196192 (1980-04-01), Kuo
patent: 4468379 (1984-08-01), Gottlieb
patent: 4518584 (1985-05-01), Mark et al.
patent: 4572834 (1986-02-01), Stout
patent: 4604377 (1986-08-01), Fernandes et al.
patent: 4613500 (1986-09-01), Suzuki et al.
patent: 4619827 (1986-10-01), Bull et al.
patent: 4780313 (1988-10-01), Koichiro et al.
patent: 4789658 (1988-12-01), Yoshimoto et al.
patent: 4840934 (1989-06-01), Anderson
patent: 5100664 (1992-03-01), Doyle et al.
patent: 5503841 (1996-04-01), Doyle et al.
patent: 5643565 (1997-07-01), Doyle et al.
Colizi, Int. and Immunity 45:25-28 (1984).
Creekmore et al., J. Clinical Oncology 7(2):276-284 (1989).
Donohue et al., J. Immunol. 130:2203-2208 (1983).
Donohue et al., Cancer Research 44:1380-1386 (1984).
Homberg et al., J. Immunol. 130:2644-2650 (1983).
Kakumu et al., J. Clin. Lab. Immunol. 26:25-27 (1988).
McFeeters and Nadler, 20th Meeting of Fed. Amer. Soc. for Exp. Biology, Apr. 13-18 (1986), Fed. Proc. 45(3):633 (1986).
Merlizzi et al., Eur. J. Immunopharmac. 7:31-34 (1985).
Mills, J. Immunol. 125:1904-1909 (1980).
Ralph et al., J. Immunol. 133:2442-2445 (1984).
Reed et al., J. Immunol. 133:3333-3337 (1984).
Weinberg et al., J. Immunol. 140(1):294-299 (1988).
The Shorter Bergey's Manual of Determinative Bacteriology, Eighth Edition, John G. Holt, Ed. (1977) pp. 135 & 136, published by the Williams & Wilkins Co., Baltimore, MD USA 21202.
Donohue et al., "In Vivo Administration of Purified Jurkat-derived Interleukin 2 in Mice", Cancer Research, (1984) 44:1380-1386.
Flomenberg et al., "Immunologic Effects of Interleukin 2 in Primary Immunodeficiency diseases", J. Immunol., (1983) 130(6):2644-2650.

Affiliated with

Also associated with

Rating

Human IL-2 as a vaccine adjuvant does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human IL-2 as a vaccine adjuvant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human IL-2 as a vaccine adjuvant will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1062222